Tranilast inhibits TGF-β1 secretion without affecting its mRNA levels in conjunctival cells

スポンサーリンク

概要

• 論文の詳細を見る

• The present study was conducted to assess the effect of Tranilast, a drug developed as anti-keloid and anti-hypertrophic scar agent, on the level of transforming growth factor-β1 (TGF-β1) mRNA, and on TGF-β1 secretion in Chang Conjunctiva cells. TGF-β1 mRNA was not detected in Chang Conjunctiva cells by Northern blot analysis, but reverse transcriptase-polymerase chain reaction (RT-PCR) analysis confirmed the presence of TGF-β1 mRNA. Tranilast, whereas the drug had no effect on the levels of TGF-β1 mRNA and cellular protein, time- and dose-dependently inhibited TGF-β1 secretion from Chang Conjunctiva cells in the enzyme-linked immunosorbent assay (ELISA) analysis. TGF-β1 is suggested to cause fibroblast proliferation, that obstructs aqueous humor filtration route after glaucoma filtration surgery. Tranilast, potentially inhibiting TGF-β1 secretion, therefore, could be a promising drug to prevent from scarring after glaucoma filtration surgery.

• 神戸大学の論文

著者

• CHIHARA Etsuo

  Sensho-kai Eye Institute

• Ochiai Yuko

  Shinnagata Eye Institute

• Ochiai Haruyuki

  Shinnagata Eye Institute

関連論文

• Detection of a New TIGR Gene Mutation in a Japanese Family With Primary Open Angle Glaucoma
• Scanning Laser Polarimetry Measurement with Variable Corneal Compensation Compared with Fixed Corneal Compensation
• Comparison of Optic Disc Topography Measured by Retinal Thickness Analyzer with Measurement by Heidelberg Retina Tomograph II
• Different Modes of Intraocular Pressure Reduction After Three Different Nonfiltering Surgeries and Trabeculectomy
• Tranilast inhibits TGF-β1 secretion without affecting its mRNA levels in conjunctival cells
• Preservation of corneal endothelium after pars plana tube insertion of the Ahmed glaucoma valve

スポンサーリンク